In almost 80% of NSCLC cases, oncogenic driver mutations were identified, which primarily included the KRAS, EGFR, BRAF, MET, ERBB2, ALK, RET, ROS1 and the NTRK1/2/3 genes [2]. Here, KRAS is linked to non-small cell lung carcinoma.